Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy. - Wikidata - awgldk - TriplyDB

Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.

Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.

http://www.wikidata.org/entity/Q37739477

about

Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain.Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin® protein MP0250: a preclinical study.

P2860

Q41660598-87114B88-9F75-42AC-87BC-19D855271B73 Q51732175-16BA35E2-49A9-4F81-A7AD-5E46F4C3B950

P2860

Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.

http://www.wikidata.org/entity/Q37739477

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 March 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.

@en

Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.

@nl

type

label

Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.

@en

Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.

@nl

prefLabel

Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.

@en

Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.

@nl

P1433

Q37739477-140505A3-B3C9-4B73-A8CE-C71675FD6A57

P1476

Q37739477-AD842ECF-7D63-42A4-96CF-E0271BAF364A

P2093

Q37739477-3480DF7A-A058-491C-AA40-5A989D11F802

Q37739477-A75A2285-8AA3-4A13-9163-F64F328FB416

P275

Q37739477-1F04F821-37FC-48BD-BFE5-DC29B4C4CA12

P2860

Q37739477-0036A8E0-93D8-4381-A8AD-D5EAB083FB42

Q37739477-01D5BEF7-DBAA-416D-AA92-9B7D065488A5

Q37739477-06E799F5-89FE-40A7-9E5A-D593BE6578E1

Q37739477-1174278B-8F36-4A47-86EA-786AF70B2B12

Q37739477-12957410-01F6-47A2-B44D-F73C79A98684

Q37739477-20EBB2C9-767F-4AEE-83B8-2890D77DC29C

Q37739477-23694221-8A3B-4FDA-9D2E-D204254F645B

Q37739477-29CCBF65-82B5-48B1-BDCD-DED527674AD8

Q37739477-2B44D868-E87F-4223-9165-8321D66ED7CE

Q37739477-2F6B562F-2FE6-445F-BB71-B6B6889C3650

P2888

Q37739477-75222986-14F5-4098-A3B5-45023A866C76

P304

Q37739477-DBBC8B27-0B5C-4D92-90A4-A61B6C06F430

P31

Q37739477-4578BDDF-B4EB-40C9-94B2-A145C7EB3B51

Q37739477-5EDECBFE-5168-40F9-AFB2-1B519709BBAF

P356

Q37739477-1C01C4A1-1896-4285-80EA-3810485A9948

P433

Q37739477-0CF3896A-5879-4EBD-BF31-EDAC69BC91EA

P478

Q37739477-44DB4666-48B4-4235-9D37-2F24B10C2F97

P577

Q37739477-E67A5441-D710-4FF2-B1EF-70C04929D48D

P698

Q37739477-FB9E0B93-E6F6-4651-A7CB-5E862B988438

P921

Q37739477-158B07DF-BA32-4B82-B649-19E5CDF2DA96

Q37739477-4135DFD5-F9CD-498F-9E3C-BBA9BE066AB1

Q37739477-42671AFA-1EBF-4148-A2C1-8ABF919C124C

Q37739477-494747FD-5F6F-4A9E-9199-DF164A7CF33C

Q37739477-9ECA88F1-7AC8-4433-BE34-D9E53A504467

Q37739477-AAD1A800-6828-46CB-BEB6-9E748813F0B2

Q37739477-F624A515-E40C-4D6D-80D0-DF380C5FD625

Q37739477-F66F7F9C-4DBF-4AE9-86A3-FE2E5B0DE1C5

P932

Q37739477-12D4AD84-0F39-4479-B69F-BB6F0B16146C

P356

P1433

Experimental and Molecular Medicine

P1476

Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.

@en

P2093

Hyori Kim

http://www.w3.org/2001/XMLSchema#string

Ki-Hyun Kim

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity

Targeting the hepatocyte growth factor-cMET axis in cancer therapy

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development

Met, metastasis, motility and more

Serum levels of hepatocyte growth factor in patients with breast cancer

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

A neutralizable epitope is induced on HGF upon its interaction with its receptor cMet.

P2888

P304

e307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/EMM.2017.17

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28336955

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

mechanism of action

membrane proteins

recombinant protein

proto-oncogene proteins

neoplasm proteins

P932

5382561

http://www.w3.org/2001/XMLSchema#string